ROSSUM
20.10.2021 06:02:05 CEST | Business Wire | Press release
Rossum, the artificial intelligence company that is re-inventing the way businesses send documents to each other, has raised $100m from one of the US’s best known funds, General Catalyst in what is Eastern Europe’s largest ever Series A. Previous investors, including LocalGlobe, Seedcamp, Miton and Elad Gil are participating, as Rossum looks to capitalise on surging corporate demand for automation in business processes.
Having rapidly secured market leadership in document AI technology and become the go-to software for many of Europe’s biggest companies, Rossum is creating a universal document gateway designed to help the corporate world move faster and complete transactions in minutes not weeks. Rossum’s founders, three PhD students who dropped out of university to start the business, are automating the whole business communication stack with a view to making bureaucratic, costly and time-consuming document communication frictionless and paperless.
Rossum has seen year-on-year growth of five times in the last 12 months, as established businesses and startups have woken up to the impact that Robotic Process Automation can make to their productivity and resourcing. The company’s vision of making B2B document communication frictionless, forever, has strongly resonated with businesses large and small who use the AI-based B2B platform to exchange and process all sorts of documents, seamlessly, without overhauling the existing infrastructure of email and PDF documents.
Corporate appetite for automation soars
Over 150 of Europe’s biggest and fastest growing companies including Bosch, Siemens, Veolia, EY and Adyen are using the platform to exchange and process documents such as invoices, purchase orders, quotations, financial statements and customs declarations. The cloud-based document gateway frees up human teams from onerous data entry work, links all related documents in a transaction, keeps transactions on timetable with automated data flows and integrates documents with other enterprises systems, including SAP and Oracle.
While enterprise RPA focuses on internal processes, Rossum is pioneering the automation of cross-company processes - something that was immensely challenging without advanced AI technology. Enabling the flow of documentation between companies frees up a massive amount of manpower, which has previously been devoted to tedious and soul-destroying manual document processing. Rossum estimates that its systems save its users typically over 90% of the manual work.
The $100 million funding will be used to hire more high skill engineering and AI talent at Rossum, which is seeing particularly strong demand for its products in North America, Western Europe and the Asia Pacific region. The funds will also be used to open new company hubs in the US, Europe and Asia and plans to open a research center in Prague, dedicated to B2B document communication, in co-operation with Czech universities.
Single unified enterprise solution
Rossum is investing heavily in product development, demonstrating that its AI technology leadership can apply to a wide range of use cases. While its mission of frictionless AI-enabled data capture remains central to Rossum’s software, the company is gradually automating the whole business communication stack, creating a single unified enterprise solution for communication between businesses.
The next stage of Rossum’s journey will see it expand its product and partner ecosystem around specific verticals including finance, logistics, insurance and order management. It is establishing a universal document gateway capable of handling the whole range of processes and document types of each industry. Processes from fraud detection at the start of a transaction, to approvals at the end will be built into the platform’s workflows.
“There is a hidden opportunity in the fact that every single product in the world requires hundreds of companies to cooperate, and that produces thousands of transactions. As market leaders in document AI technology, we are in a unique position to transform the way these transactions are communicated and processed. Rossum already saved billions of keystrokes in data entry for our clients. Now we are saving people’s time across the whole process of transaction handling by building an end-to-end business communication platform. Businesses large and small are waking up to the huge gains that they will make from such a system and they trust us to deliver it,” Tomas Gogar, Rossum’s CEO , said.
“Rossum spotted a problem that is so ubiquitous that we rarely even think about it. The founders realized the massive hidden opportunity, and created a disruptive solution based on an entirely new deep technology. Rossum is still early on its journey, but it has already grown into a company with worldwide reach that has had a tremendous impact on global enterprise customers,” said Trevor Oelschig, Managing Director at General Catalyst.
“It is remarkable that three AI scientists from Prague dropped out from academia to start a business and five years later they are leading a company of 140, serving some of the world’s top brands and building something exceptional. The storylines of lightning speed growth like UiPath, Celonis and now Rossum show how the CEE region is becoming a true global powerhouse of AI and Automation. Again and again, we see the combination of great business ambition and deep technical skill from this region,” said Reshma Sohoni, founding partner at Seedcamp.
“Rossum is on the cusp of an enormous market opportunity. Documents of all forms are the lifeblood of business-to-business communication, and every company in the world will want to automate this process sooner or later and Rossum is perfectly positioned to meet this need. Its world-leading AI technology for cognitive data capture means that Rossum adopters do not need to coordinate with their business partners to automate this communication,” said Mish Mashkautsan, General Partner, at LocalGlobe and Latitude.
Founded in 2016 by AI PhD students Tomas Gogar, Petr Baudis and Tomas Tunys who dropped out of university to start the business, all three were named among Financial Times' New Europe 100 Challengers and Gogar was named in Forbes' 30 under 30 list. Baudis’ PhD work is also credited in Google’s scientific paper on its historic AlphaGo AI victory in 2016.
Rossum has previously raised $9.5M in total and the existing investors also participate in the current round. Rossum’s customers include Cushman & Wakefield, BDO, Suez and PwC, while its technology is embedded in modern business technology providers such as Celonis or Flexport.
Rossum has been named one of the most promising European cloud companies in the Accel Euroscape two years in a row, and listed in the CB Insights' annual selection of the 100 most promising private AI companies in the world. Everest Group rated Rossum a ‘Star Performer’ for 2020 with regards to its market impact in the document processing space.
Customer quotes:
Jana Vlkova, Head of Accounts Payable, PepsiCo, CEE , said: "We had a never-ending backlog before we implemented Rossum. Now, we can always complete our work on time."
Michal Cipa, IT Manager , Cosco Shipping Line, said: “All our invoices are going through Rossum; I can’t imagine our paperless AP process functioning without it.”
- End -
About Rossum
Rossum is eliminating useless paperwork by automating business communication. Thousands of lifetimes per day are burned on manually dealing with documents in enterprise back offices - it’s a terrible job, and it makes the whole world go slower. Rossum’s proprietary AI engine outranks narrow data extraction solutions in accuracy and saves its users typically over 90% of the manual work. Rossum serves hundreds of the world’s best companies ranging from business software vendors like Celonis to Fortune 500 class enterprises such as Bosch, Cushman & Wakefield, COSCO Shipping, Delivery Hero, Deloitte, EY, K+S, Molson Coors, PepsiCo, Siemens, Suez and Veolia. Rossum is funded by the top venture capital funds in London and the most experienced Silicon Valley angels and has already saved over five billion keystrokes globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005884/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
